Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients
OKT3, a murine monoclonal antibody specific to the human CD3 complex, induces immunosuppression by depletion of T cells. Administration of OKT3 results in significant release of proinflammatory cytokines, such as TNFα and IL1β. Liver recipients who experience rejection within 3 weeks after transplan...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2000-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1080/09629350020002877 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566805405630464 |
|---|---|
| author | Sasan Roayaie Patricia A. Sheiner Sukru Emre Steven Guy Myron E. Schwartz Peter Boros Charles M. Miller |
| author_facet | Sasan Roayaie Patricia A. Sheiner Sukru Emre Steven Guy Myron E. Schwartz Peter Boros Charles M. Miller |
| author_sort | Sasan Roayaie |
| collection | DOAJ |
| description | OKT3, a murine monoclonal antibody specific to the human CD3 complex, induces immunosuppression by depletion of T cells. Administration of OKT3 results in significant release of proinflammatory cytokines, such as TNFα and IL1β. Liver recipients who experience rejection within 3 weeks after transplantation with OKT3 prophylaxis recover their T cells by postoperative day 10 despite complete initial clearance. |
| format | Article |
| id | doaj-art-285de3081b774828b6e34c30773a8845 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2000-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-285de3081b774828b6e34c30773a88452025-02-03T01:03:04ZengWileyMediators of Inflammation0962-93511466-18612000-01-0193-414114610.1080/09629350020002877Cytokine profiles in early rejection following OKT3 treatment in liver transplant patientsSasan Roayaie0Patricia A. Sheiner1Sukru Emre2Steven Guy3Myron E. Schwartz4Peter Boros5Charles M. Miller6The Recanati/Miller Transplantation Institute, The Mount Sinai School of Medicine, Box 1504, One Gustave L. Levy Place, New York 10029, NY, USAThe Recanati/Miller Transplantation Institute, The Mount Sinai School of Medicine, Box 1504, One Gustave L. Levy Place, New York 10029, NY, USAThe Recanati/Miller Transplantation Institute, The Mount Sinai School of Medicine, Box 1504, One Gustave L. Levy Place, New York 10029, NY, USAThe Recanati/Miller Transplantation Institute, The Mount Sinai School of Medicine, Box 1504, One Gustave L. Levy Place, New York 10029, NY, USAThe Recanati/Miller Transplantation Institute, The Mount Sinai School of Medicine, Box 1504, One Gustave L. Levy Place, New York 10029, NY, USAThe Recanati/Miller Transplantation Institute, The Mount Sinai School of Medicine, Box 1504, One Gustave L. Levy Place, New York 10029, NY, USAThe Recanati/Miller Transplantation Institute, The Mount Sinai School of Medicine, Box 1504, One Gustave L. Levy Place, New York 10029, NY, USAOKT3, a murine monoclonal antibody specific to the human CD3 complex, induces immunosuppression by depletion of T cells. Administration of OKT3 results in significant release of proinflammatory cytokines, such as TNFα and IL1β. Liver recipients who experience rejection within 3 weeks after transplantation with OKT3 prophylaxis recover their T cells by postoperative day 10 despite complete initial clearance.http://dx.doi.org/10.1080/09629350020002877 |
| spellingShingle | Sasan Roayaie Patricia A. Sheiner Sukru Emre Steven Guy Myron E. Schwartz Peter Boros Charles M. Miller Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients Mediators of Inflammation |
| title | Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients |
| title_full | Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients |
| title_fullStr | Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients |
| title_full_unstemmed | Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients |
| title_short | Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients |
| title_sort | cytokine profiles in early rejection following okt3 treatment in liver transplant patients |
| url | http://dx.doi.org/10.1080/09629350020002877 |
| work_keys_str_mv | AT sasanroayaie cytokineprofilesinearlyrejectionfollowingokt3treatmentinlivertransplantpatients AT patriciaasheiner cytokineprofilesinearlyrejectionfollowingokt3treatmentinlivertransplantpatients AT sukruemre cytokineprofilesinearlyrejectionfollowingokt3treatmentinlivertransplantpatients AT stevenguy cytokineprofilesinearlyrejectionfollowingokt3treatmentinlivertransplantpatients AT myroneschwartz cytokineprofilesinearlyrejectionfollowingokt3treatmentinlivertransplantpatients AT peterboros cytokineprofilesinearlyrejectionfollowingokt3treatmentinlivertransplantpatients AT charlesmmiller cytokineprofilesinearlyrejectionfollowingokt3treatmentinlivertransplantpatients |